A
Avertix Medical
A heart-attack warning system that can detect abnormal changes in heart activity and provide an immediate alert if a heart attack is onset
About Avertix Medical
Avertix operates in the medical device industry, focusing on cardiovascular health. The company's flagship product, the Guardian, is the first and only FDA-approved heart attack warning system. It provides continuous 24/7 monitoring and real-time alerts for abnormal changes in activity, including silent heart attacks. The Guardian system aims to reduce pre-hospital delay, which can significantly improve patient outcomes by ensuring timely medical intervention. The device is available by prescription or physician order in the USA. Avertix primarily serves patients at high risk of recurrent heart attacks, including those with diabetes, kidney disease, or multi-vessel coronary disease. The business model revolves around the sale of the Guardian system and related monitoring services, generating revenue through direct sales to healthcare providers and patients. The company operates in a niche market with a high unmet medical need, offering a unique solution that enhances the diagnosis and management of life-threatening heart conditions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 61.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotechnology, Biotech and Pharma, SPAC Target, SPAC IPO Announced, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Sep 2024 | $15M | — | Undisclosed | ↗ |
| SPAC IPOOther financing | May 2023 | $200M | $200M | BIOS Acquisition Corporation (dba BioPlus Acquisition Corp) | ↗ |
Growth signals
Latest recorded traffic for Avertix Medical is 3.5K monthly website visits, up 84.2% over the last three months. Avertix Medical's team declined 26.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Avertix Medical in the Eatontown ecosystem
The Avertix Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- BCBIOS Acquisition Corporation (dba BioPlus Acquisition Corp)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avertix Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avertix Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









